XmAb 5871

Drug Profile

XmAb 5871

Alternative Names: AMG 729; XmAb® 5871

Latest Information Update: 28 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xencor
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; Fc gamma receptor IIB modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 16 Jun 2017 Interim efficacy data from a phase II trial in Autoimmune disorders presented at the Annual European Congress of Rheumatology (EULAR-2017)
  • 11 May 2017 XmAb 5871 receives Orphan Drug status for Autoimmune disorders in USA
  • 09 May 2017 Adverse events data from a phase I trial in Healthy volunteers released by Xencor
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top